(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Fossils from China show complex life evolved millions of years earlier than once thought - 2Dominating the Art of Composing: Creator Bits of knowledge
- 3Tatiana Schlossberg, JFK's granddaughter, dies at 35 after terminal cancer diagnosis
- 4Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain
- 5Your guide to how to safely thaw and cook your Thanksgiving turkey this year, according to experts
- Jasmine Crockett in, Colin Allred out: A major shakeup for Democrats in their quest to finally win a Senate seat in Texas
- Reports: Germany plans expansion of foreign intelligence powers
- Audits of the Top Science fiction Movies This Year
- 10 Natural products to Remember for Your Eating routine for a Better You
- Which Film Has the Incomparable Melodic Score?
- Pick Your Favored method of transportation
- 21 Incredibly Entertaining Contemplations To Observe Consistently
- Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
- German finance minister sees advantages of smartphones in schools
